Crenolanib

670220-88-9

C26H29N5O2

DMSO : 33.33 mg/mL (75.15 mM; Need ultrasonic)

Protein Tyrosine Kinase/RTK; Protein Tyrosine Kinase/RTK; Autophagy

Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRalpha/beta with K_ds of 0.74 nM and 2.1 nM/3.2 nM, respectively. IC50 & Target: Kd: 2.1 nM (PDGFRalpha), 3.2 nM (PDGFRbeta), 0.74 nM (FLT3) In Vitro: Crenolanib has 25-fold more affinity for PDGFRA/B compared with KIT, and is approximately 135-fold more potent than STI571 for inhibiting the PDGFRA D842V mutation. The IC₅₀ for crenolanib for a KIT exon 11 deletion mutant kinase is greater than 1, 000 versus 8 nM for STI571. Crenolanib has low nanomolar potency against the V561D + D842V-mutant kinase that is similar to its potency against the isolated D842V mutation. Both STI571 and crenolanib potently inhibit the kinase activity of the fusion oncogene with IC₅₀ values of 1 and 21 nM, respectively, and inhibits PDGFRA activation in this cell line with IC₅₀ values of 93 and 26 nM, respectively^[1]. HL60/VCR and K562/ABCB1 cells, overexpressing ABCB1, are 6.9- and 3.6-fold resistant to crenolanib, respectively, in relation to parental HL60 and K562 cells. PSC-833 fully reverses resistance to crenolanib in both HL60/VCR and K562/ABCB1 cells. Crenolanib (1 nM-10 uM) stimulates ABCB1 ATPase activity in a concentration-dependent manner. Crenolanib treatment does not increase the cell surface expression of ABCB₁. Crenolanib inhibits [¹²⁵I]-IAAP photocrosslinking of ABCB1 at high concentrations, with 50 % inhibition at 10 uM, but has little effect at lower concentrations, below 1 uM^[2]. Crenolanib decreases NSCLC cell viability, induces apoptosis in NSCLC cells, and inhibits cell migration in NSCLC cells^[3]. In Vivo: Crenolanib (10 mg/kg and 20 mg/kg) suppresses non-small-cell lung cancer tumor growth in vivo and induces tumor cell apoptosis, and the dosage of crenolanib applied is well tolerated by recipient mice^[3].